CHARIOTMS is a groundbreaking clinical trial.
It will test whether Cladribine Tablets (MAVENCLAD©), an established treatment for highly active relapsing MS, can preserve upper limb function in Advanced MS, where people have largely lost the ability to walk.
These are the 44% of people with MS who currently have very limited treatment options.
CHARIOTMS is the first disease modifying treatment trial for wheechair users .
CHARIOTMS is the first trial with no upper age limit.
Prof Klaus Schmierer,
Chief Investigator, ChariotMS
Barts NHS Health Trust
SARS-CoV2 Risk Mitigation (PDF tba
Check your local NHS Trustfor updates